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Background: Colorectal cancer is one of the main cancers in the Western world. About 90% of the deaths arise
from formation of distant metastasis. The expression of the newly identified gene metastasis associated in colon
cancer 1 (MACC1) is a prognostic indicator for colon cancer metastasis. Here, we analyzed for the first time the
impact of single nucleotide polymorphisms (SNPs) in the coding region of MACC1 for clinical outcome of colorectal
cancer patients. Additionally, we screened met proto-oncogene (Met), the transcriptional target gene of MACC1,
for mutations.
Methods: We sequenced the coding exons of MACC1 in 154 colorectal tumors (stages I, II and III) and the crucial
exons of Met in 60 colorectal tumors (stages I, II and III). We analyzed the association of MACC1 polymorphisms
with clinical data, including metachronous metastasis, UICC stages, tumor invasion, lymph node metastasis and
patients’ survival (n = 154, stages I, II and III). Furthermore, we performed biological assays in order to evaluate the
functional impact of MACC1 SNPs on the motility of colorectal cancer cells.
Results: We genotyped three MACC1 SNPs in the coding region. Thirteen % of the tumors had the genotype cg
(rs4721888, L31V), 48% a ct genotype (rs975263, S515L) and 84% a gc or cc genotype (rs3735615, R804T). We found
no association of these SNPs with clinicopathological parameters or with patients’ survival, when analyzing the
entire patients’ cohort. An increased risk for a shorter metastasis-free survival of patients with a ct genotype
(rs975263) was observed in younger colon cancer patients with stage I or II (P = 0.041, n = 18). In cell culture,
MACC1 SNPs did not affect MACC1-induced cell motility and proliferation.
Conclusion: In summary, the identification of coding MACC1 SNPs in primary colorectal tumors does not improve
the prediction for metastasis formation or for patients’ survival compared to MACC1 expression analysis alone. The
ct genotype (rs975263) might be associated with a reduced survival for younger colon cancer patients in early
stages. However, further studies with larger sample sizes are needed.
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Colorectal cancer is the third most common form of
cancers in the Western world.1 The 5-year-survival rate
of colorectal cancer patients with a local tumor is about
90%, whereas only around 10% of the patients survive
when distant metastases have formed [1-3].* Correspondence: ustein@mdc-berlin.de
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reproduction in any medium, provided the orIn an earlier study the new gene metastasis associated
in colon cancer 1 (MACC1) was identified by differential
display RT-PCR [4]. MACC1 is a prognostic marker for
distant metastasis formation and allows the identifica-
tion of colorectal cancer patients with a high risk for
metastatic cancer. Tumors, staged I to III, which devel-
oped metachronously metastases, showed a significantly
higher MACC1 expression compared to non-
metastasizing tumors. The 5-year survival rate for
patients with high MACC1 expression in the primary
tumors was only 15% compared to 80% for subjects withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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key regulator of met proto-oncogene (Met) expression
[4,5]. The hepatocyte growth factor (HGF)-Met pathway
plays a decisive part in epithelial-mesenchymal transi-
tion, cell motility, invasiveness, and metastasis [6,7].
Overexpression of MACC1 results in Met expression in-
duction and thereby enhances the activation of the
MAPK (mitogen-activated protein kinase)-signaling [4].
Various Met mutations are described that lead to high
tumorigenicity. Variants of Met were found in many
tumor entities, including colon cancer [8-15]. In contrast
to Met mutations, MACC1 mutations in tumors have
not yet been studied. In databases, single nucleotide
polymorphisms (SNPs) are annotated for MACC1. The
three MACC1 SNPs identified in this study (rs4721888,
rs975263 and rs3735615) are also annotated in data-
bases. However, their occurrence and frequencies in pri-
mary tumors and their association with tumor
progression and metastasis are unknown.
Thus, the overriding aim of our study was the evalu-
ation of MACC1 SNPs for prognostication of patients’
survival. For the first time, we analyzed the mutation
status of coding MACC1 exons in colorectal tumors and
studied the association of MACC1 SNPs with clinico-
pathological data, including gender, age, tumor stages,
lymph node involvement and, in particular, with the de-
velopment of distant metastases as well as with overall
and metastasis-free survival. Furthermore, we studied
the functional effect of the identified MACC1 SNPs on
the migratory, proliferative or wound healing potential
of colorectal cancer cells by in vitro assays. In addition,
we screened the crucial exons of the proto-oncogene
Met in colorectal tumors for mutations.
Results
MACC1 SNPs and Met variants in primary
colorectal tumors
We screened the coding exons of MACC1 for muta-
tions and identified the MACC1 genotype cg (31 VL,
rs4721888), ct (515 SL, rs975263) and gc or cc (804 RT
or 804 TT, rs3735615) in a first panel of 60 colorectal
tumors. In order to validate these findings, we
screened for these genotypes in a second set of further
94 colorectal tumors and found them as frequent as in
the first tumor panel. Thirteen % of the tumors had the
genotype cg (31 VL, rs4721888), 48% the ct genotype
(515 SL, rs975263,) and 84% a gc or cc genotype (804
RT or 804 TT, rs4721888). Tumors with the variant 31
VL (rs4721888) harbored always the variant 515 SL
(rs975263) and variant 804 RT or TT (rs4721888) sim-
ultaneously. Furthermore, almost every tumor (97%)
with 515 SL (rs975263) also carried the variant 804 RT
or 804 TT (rs4721888) (Additional file 1: Table S1). All
SNPs were in Hardy-Weinberg-Equilibrium (rs4721888:P = 0.39, rs975263: P = 0.07, rs3735615: P = 1.0). The
identified SNPs were in low linkage disequilibrium with
r2 of 0.05, 0.19 and 0.20 demonstrating that the alleles
are randomly distributed. The SNPs are located in the
coding MACC1 exons 4 (L31V, rs4721888), 5 (S515L,
rs975263) and 7 (R804T, rs3735615) (Figure 1A). In the
protein structure the variant L31V appears close to the
N-terminus of the MACC1 protein; the polymorphism
S515L is located shortly before a putative proline-rich
domain, whereas R804T occurs in a putative second
death domain of the MACC1 protein (Figure 1A).
Furthermore, we studied the coding exons 14 to 19 of
one of the transcriptional targets of MACC1, the proto-
oncogene Met, in the first 60 colorectal tumors. For this
mutation analysis we chose the juxtamembrane and the
kinase domain because most of the already described
mutations were found in these domains and were
described to affect the function of this receptor tyrosine
kinase [8,15]. We found only two tumors with Met
mutations: in one tumor the variant R988C (rs45607832)
and in a second tumor the variant T1010I (rs56391007)
(Figure 1B). Both variants occurred in the juxtamembrane
domain (exon 14) of the receptor (Figure 1B). Because of
the low minor allele frequency no further tumors were
sequenced.
MACC1 SNPs have no impact on MACC1 expression
We analyzed the MACC1 mRNA expression in the set
of 60 colorectal tumors (Figure 2A). We compared each
SNP to the mRNA expression of MACC1 in the tumors
and did not find an association of the SNPs with
MACC1 expression (L31V: P = 0.08, S515L: P = 0.28,
R804T: P = 0.11, R804T homozygous: P = 0.55).
Moreover, we evaluated the impact of the identified
SNPs on the expression of MACC1 in cell culture. We
used the colorectal cancer cell lines SW480, DLD1 and
HCT116. We introduced SNPs into the wild-type
MACC1 sequence by site-directed mutagenesis, cloned
the plasmids pcDNA3.1/MACC1/wt, pcDNA3.1/
MACC1/L31V, pcDNA3.1/MACC1/S515L, pcDNA3.1/
MACC1/R804T, and transfected SW480, DLD1 and
HCT116 cells with these constructs. MACC1-transfected
cells had an increased MACC1 mRNA (P < 0.01, P <
0.0001, P < 0.01) and protein expression levels com-
pared to parental cells. The identified SNPs, however,
did not influence the MACC1 mRNA (P = 0.37, P =
0.54, P = 0.99) or protein expression levels compared to
SW480/MACC1/wt, DLD1/MACC1/wt or HCT116/
MACC1/wt cells (Figure 2B).
MACC1 SNPs do not affect motility and proliferation of
colorectal cancer cells
In order to evaluate the impact of MACC1 SNPs on the
biological functions of MACC1 we performed in vitro
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with the MACC1 constructs pcDNA3.1/MACC1/wt,
pcDNA3.1/MACC1/L31V, pcDNA3.1/MACC1/S515L,Figure 1 Genotyped MACC1 SNPs rs4721888, rs975263,
rs3735615 and Met variants rs45607832 and rs56391007 in
primary colorectal tumors. A) The chromatograms show the
wild-type and the MACC1 sequences with the variants. Sites of
nucleotide exchanges are indicated by arrow. Location of SNPs in
the MACC1 protein structure is marked. Cla: clathrin box, PxxP:
proline-rich domain, DD: death domain. B) The sequencing
chromatograms of two sequences with Met variants R988C and
T1010I are shown. Both variants are in the juxtamembrane domain
of the Met receptor. Cys: cysteine-rich domain, Ig: immunoglobuline
domain, TM: transmembrane domain, TK: tyrosine kinase domain.pcDNA3.1/MACC1/R804T were used for these bio-
logical assays. We evaluated the migratory impact of
SW480, DLD1 and HCT116 cells and transfectants
thereof (Figure 3A). We previously demonstrated
increased SW480 cell migration ability of wild-type
MACC1 transfectants compared to parental SW480 cells
[4]. In this study, we also observed an about 3-fold
increased cell migration of SW480/MACC1/wt, a 1.7-
fold increased cell migration of DLD1/MACC1/wt and
of HCT116/MACC1/wt cells compared to the parental
cell lines (P < 0.01, P < 0.001, P < 0.001). However, this
MACC1-induced cell migration was comparable in all
MACC1-transfected cell clones independent of the
introduced SNPs. Thus, the MACC1 SNPs L31V, S515L,
and R804T have no impact on the migratory ability of
colorectal cancer cells (P = 0.77, P = 0.12, P = 0.27)
(Figure 3A).
Moreover, we studied the proliferative potential of the
transfected cells. Cells with one of the constructs
pcDNA3.1/MACC1/L31V, pcDNA3.1/MACC1/S515L or
pcDNA3.1/MACC1/R804T showed the same ability for
proliferation as cells with the wild-type construct. Thus,
none of the SNPs affects the proliferative potential of
these colorectal cancer cells (Figure 3B).
Furthermore, we analyzed the wound healing ability of
these cells. MACC1 promotes the ability of cells to close
a wound [4]. We confirmed that SW480/MACC1/wt,
DLD1/MACC1/wt and HCT116/MACC1/wt cells do
close the wound area faster than parental cells, but
transfectants harboring the MACC1 SNPs L31V, S515L,
and R804T did not demonstrate an altered potential for
directed migration (Figure 3C).
MACC1 SNPs and association with metastasis or
clinicopathological parameters
We analyzed if variants 31 LV, 515 SL or 804 RT or 804
TT are associated with clinicopathological factors of all
154 patients (Table 1). We compared each polymorph-
ism to the formation of metachronous metastasis of the
subjects, to age and gender of the patients, and to clin-
ical parameters including UICC-stages, tumor or lymph
node infiltration. None of the parameters is significantly
associated with any of the identified polymorphisms (for
details see Table 1).
MACC1 SNPs and association with overall survival (OS)
and metastasis-free survival (MFS) in all colorectal
cancer patients
We analyzed OS and MFS of all 154 colorectal cancer
patients with variants 31 LV, 515 SL, 804 RT or 804 TT.
We did not find an association with OS or MFS of all
patients with any of the identified MACC1 SNPs (OS:
P = 0.77, HR = 1.14, 95% CI = 0.49-2.66; MFS: P = 0.71,
HR = 1.21, 95% CI = 0.44-3.38) (Figure 4.1A). When
Figure 2 MACC1 SNPs L31V, S515L, and R804T and MACC1 expression in colorectal cells and tumors A). MACC1 mRNA expression was
determined in 60 colorectal tumors by qRT-PCR. Box plots show the mRNA expression compared to MACC1 genotypes. SNPs have no effect on
the MACC1 mRNA expression in these colorectal tumors. B) SW480, DLD1, HCT116 colorectal cancer cells were transfected with pcDNA3.1/
MACC1/wt, pcDNA3.1/MACC1/L31V, pcDNA3.1/MACC1/S515L and pcDNA3.1/MACC1/R804T. The MACC1 mRNA expression in these cell clones
was measured by qRT-PCR and normalized to the MACC1 mRNA expression of parental cells. Additionally, MACC1 protein expression was
determined. β-tubulin was used as a loading control. SNPs have no effect on the MACC1 mRNA and protein expression in SW480, DLD1 and
HCT116 colorectal cancer cells.
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the SNPs with OS or MFS was found: 31 LV (OS: P = 0.79,
HR = 0.88, 95% CI = 0.36-2.18, MFS: P = 0.40, HR = 1.62,
95%CI = 0.53-4.97, Figure 4.1B); 515 SL (OS: P = 0.68,
HR = 0.88, 95% CI = 0.48-1.60, MFS: P = 0.21, HR = 0.63,
95% CI = 0.30-1.30, Figure 4.1 C), patients with variant 804
RT or 804 TT had no decreased survival time (804 RT: OS:
P = 0.98, HR = 0.99, 95% CI = 0.44-2.22, MFS: P = 0.91, HR
= 1.06, 95% CI = 0.40-2.82, Figure 4.1 D; 804 TT: OS: P =
0.81, HR = 1.08, 95% CI = 0.58 - 2.01, MFS: P = 0.62, HR =
1.22, 95% CI = 0.57-2.60, Figure 4.1 E).
Combinations of SNPs, e.g. patients with the variant
allele 31 LV and 515 SL, with 31 LV and 804 RT/TT, or
with 515 SL and 804 RT/TT, compared to patients with-
out any SNP or with only one SNP did not improve sur-
vival prognosis.Younger colon cancer patients of early stages with a
genotype 515 SL have a reduced MFS
When we determined the MFS time of a small group (n
= 18) of the 154 colorectal cancer patients we found an
association of the MFS time with the genotype 515 SL
(Figure 5). Patients with colon cancer in UICC-stage I orII who are younger than 60 years (age at diagnosis) had
a reduced MFS time when they harbored the T-allele
compared to patients with the C-allele (P = 0.041, HR =
0.09, 95% CI = 0.01-0.91).Discussion
The metastasis-inducing gene MACC1 is a newly identi-
fied gene and its expression is a prognostic indicator for
colorectal cancer metastasis [4]. In this study, we identi-
fied the SNPs rs4721888, rs975263, rs3735615 in the cod-
ing region of MACC1 in primary colorectal tumors. We
analyzed the association of the MACC1 SNPs with clinical
parameters such as age, gender as well as with metachro-
nous metastasis, UICC-stages, tumor and lymph node in-
filtration. However, none of the identified variants 31 LV,
515 SL, and 804 RT or 804 TT was associated with one of
these parameters. Furthermore, the identified SNPs were
neither associated with OS nor with MFS in the entire co-
hort of colorectal cancer patients analyzed. However, colon
cancer patients classified to UICC-stage I or II and younger
than 60 years old with a 515 SL variant had a decreased
MFS time. Thus, the T-allele of this SNP might be asso-
ciated with the survival of younger patients with an early
Figure 3 (See legend on next page.)
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Figure 3 MACC1 SNPs L31V, S515L, and R804T, cell motility, and proliferation in colorectal cancer cells. A) SW480, DLD1 and HCT116
colorectal cancer cells were transfected with pcDNA3.1/MACC1/wt, pcDNA3.1/MACC1/L31V, pcDNA3.1/MACC1/S515L and pcDNA3.1/MACC1/
R804T. Cell migration was analyzed using Boyden chamber assay. SNPs have no effect on the migratory abilities of the cells. B) The proliferation
of SW480, DLD1, HCT116 and transfected cells was analyzed by MTT assay. SNPs do not affect the proliferative potential of the cells. C) For the
wound healing assay SW480, DLD1, HCT116 and transfected cells were seeded and scratched. The wound healing area was documented until
day 4. Cells with MACC1 SNPs show the same abilities to close the wound compared to cells with wild-type MACC1.
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is very small and validation by comprehensive cohorts is
necessary.
We identified three different MACC1 SNPs and two
Met variants in the colorectal tumors that are already
annotated in the NCBI SNP database. The occurrence
and frequencies of MACC1 SNPs in primary tumors of
colorectal cancer patients were unknown but their fre-
quencies in different non-cancer populations can be
found in SNP databases. Only two tumors showed var-
iants of the proto-oncogene Met. Other studies con-
firmed that Met mutations are rare events [11,16].
Tyner and colleagues reported that the variant R988C
occurs only in 1% (95% CI = 0-5%) and T1010I in 0%
(95% CI = 0-3%) of 109 colorectal tumors [11]. In our ana-
lyzed tumors both Met variants appear in only 1.6% of all
tumors. The effects of the Met variants are controversially
discussed. Schmidt et al. reported that T1010I does not
result in a constitutive phosphorylation of Met in NIH3T3
cells [15]. Lee et al. confirmed the conclusion, but showed
that mice tumors with this Met variant grow slightly faster
[12]. Finally, Tyner et al. described no difference in the
transforming capacity or in the phosphorylation status of
the variants compared to the wild-type receptor [11]. Due
to the few Met variants in our tumor panel a correlation
to clinical data was not possible.
It was shown that various SNPs of cancer-related
genes are associated with a higher risk or a faster pro-
gression of cancers [17-19]. Examples of activating
mutations are the missense mutations in codon 12 or 13
of the KRAS genes that lead to conformational changes
in the KRAS protein [20]. In SNP databases 55 missense
SNPs in the coding region of MACC1 are annotated. All
three identified MACC1 SNPs in this study are missense
alterations. SNP L31V leads to an amino acid exchange
from leucine to valine. An influence on the protein
structure is disputable because both amino acids belong
to the group of nonpolar amino acids. SNP S515L
results in a substitution of serine for leucine. Here, a
polar charged amino acid is replaced by a nonpolar one
and this may result in a loss of a possible phosphoryl-
ation site. SNP R804T exchanges the amino acid se-
quence from arginine to threonine that potentially can
act as phosphorylation site. Thus, an effect on the pro-
tein function could be possible. We used SIFT and Poly-
phen software tools for the estimation of functionalimpact [21,22]. Both programs predict that the 31 VL
and 515 SL variants are probably benign, whereas 804
RT could be damaging. R804T lies in a conserved do-
main and might have therefore a decisive role. SNPs
L31V and S515L are not in predicted domains of the
protein structure, whereas R804T can be found in a pu-
tative death domain. So far, the MACC1 protein domain
architecture was exclusively studied by bioinformatical
approaches [23]. Further efforts are required to elucidate
the MACC1 protein structure in order to evaluate the
importance of the identified SNPs. We analyzed the pos-
sible effect of these MACC1 SNPs on the protein func-
tion by biological in vitro assays. First, we showed that
the SNPs do not change the expression level of MACC1.
We then performed migration and proliferation assays
but did not observe an influence of the SNPs on the be-
havior of the colorectal cancer cells. The MACC1 vari-
ant 804 RT or 804 TT which was predicted as possibly
damaging did not have a functional impact on cell mi-
gration and proliferation studies.
This study has some limitations. First, as already men-
tioned, the MACC1 SNP analysis should also be carried
out with a larger cohort of patients. Further efforts
should be made in order to evaluate if the MACC1 SNPs
are germline or somatic polymorphisms and if they
occur in other tumor entities. Moreover, other regions
of the MACC1 gene that are more likely related to its
expression, such as the promoter region or the 3’UTR
where possible miRNAs could bind, should be explored.
Conclusion
Taken together, the analysis of the coding MACC1 var-
iants 31 LV, 515 SL, 804 RT or 804 TT in primary colo-
rectal tumors does not improve the prediction for
metastasis formation or for patients’ survival compared
to MACC1 expression analysis alone. Thus, a general
screening for these MACC1 SNPs in colorectal cancer
patients is not recommended. This first study suggests
that the MACC1 SNP S515L should be validated in a
further study in order to prove a possible prognostic
value for this SNP.
Methods
Patients
In total, 154 patients with pathologically confirmed pri-
mary colorectal tumors (adenocarcinomas) with UICC-
Table 1 Association of MACC1 SNPs with clinicopathological factors
rs4721888 (L31V)
Parameters Leu/Leu (ctc/ctc) (%) Leu/Val (ctc/gtc) (%) P-value OR 95% CI
All tumors, n = 154 134 (87%) 20 (13%)
Metachronous metastasis,
n = 29
27 (93%) 2 (7%) 0.28 0.44 0.10 - 2.02
Gender male, n = 79 68 (86%) 11 (14%) 0.72 1.19 0.46 - 3.05
Age > 66.32 years (median),
n = 77
67 (87%) 10 (13%) 1.00 1.00 0.39 – 2.56
pT3 and pT4, n = 118 102 (86%) 16 (14%) 0.70 1.26 0.39 - 4.03
N1 to N3, n = 53 43 (81%) 10 (19%) 0.12 2.12 0.82 - 5.47
UICC stage I, n = 26 24 (92%) 2 (8%) 0.38 0.51 0.11 - 2.34
UICC stage II, n = 74 66 (89%) 8 (11%) 0.44 0.69 0.26 - 1.79
UICC stage III, n = 54 44 (81%) 10 (19%) 0.13 2.05 0.79 - 5.28
rs975263 (S515L)
Parameters Ser/Ser (tcg/tcg) (%) Ser/Leu (tcg/ttg) (%) P-value OR 95% CI
All tumors, n = 154 80 (52%) 74 (48%)
Metachronous metastasis,
n = 29
12 (41%) 17 (59%) 0.21 1.69 0.75 – 3.83
Gender male, n = 79 40 (51%) 39 (49%) 0.74 1.11 0.59 - 2.10
Age > 66.32 years (median),
n = 77
40 (52%) 37 (48%) 1.00 1.00 0.53 – 1.88
pT3 and pT4, n = 118 63 (53%) 55 (47%) 0.52 0.78 0.37 - 1.65
N1 to N3, n = 53 26 (49%) 27 (51%) 0.60 1.19 0.61 - 2.32
UICC stage I, n = 26 14 (54%) 12 (46%) 0.83 0.91 0.39 - 2.13
UICC stage II, n = 74 39 (53%) 35 (47%) 0.86 0.94 0.50 - 1.78
UICC stage III, n = 54 27 (50%) 27 (50%) 0.72 1.13 0.58 - 2.19
rs3735615 (R804T) without R804T compared to with R804T
Parameters Arg/Arg (aga/aga) (%) Arg/Thr (aga/aca) (%) Thr/Thr (aca/aca) (%) P-value OR 95% CI
All tumors, n = 154 25 (16%) 74 (48%) 55 (36%)
Metachronous metastasis,
n = 29
5 (17%) 15 (52%) 9 (31%) 0.95 0.96 0.33 - 2.80
Gender male, n = 79 11 (14%) 37 (47%) 31 (39%) 0.43 1.42 0.60 - 3.36
Age > 66.32 years (median),
n = 77
12 (16%) 39 (51%) 26 (34%) 0.83 1.10 0.47 - 2.59
pT3 and pT4, n = 118 21 (18%) 53 (45%) 44 (37%) 0.34 0.58 0.18 - 1.81
N1 to N3, n = 53 9 (17%) 27 (51%) 17 (32%) 0.86 0.92 0.38 - 2.25
UICC stage I, n = 26 4 (15%) 14 (54%) 8 (31%) 0.90 1.08 0.34 - 3.46
UICC stage II, n = 74 12 (16%) 32 (43%) 30 (41%) 1.00 1.00 0.43 - 2.36
UICC stage III, n = 54 9 (17%) 28 (52%) 17 (32%) 0.91 0.95 0.39 - 2.33
SNPs are not associated with clinicopathological data like metachronous development of distant metastases, gender, age (median: 66.32 years), tumor stages (pT3,
pT4), lymph node status (N1 to N3: with lymph node metastases) and UICC stages. Ser: serine, Leu: leucine, Arg: arginine, Thr: threonine. P-values were
determined by using Chi-Square test and odds ratios (OR) with 95% confidence intervals (95% CI) were calculated.
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hensive overview of patients’ data is shown in Table 2.
Primary colorectal tumors were obtained from all
patients with informed written consent (approved by the
local ethics committee of the Charité, Berlin). Tumor
staging and typing was performed according to UICC
and WHO guidelines. The subjects were previouslyuntreated, did not have a history of familial colorectal
cancer, did not suffer from a second tumor of the same
or a different entity, and underwent surgical R0 resec-
tion. Twenty-nine subjects developed metachronously
distant metastases. The follow-up data of all patients
was documented for more than 5 years and up to 14
years (with a median follow-up of 6.3 years) after
Figure 4 (See legend on next page.)
Schmid et al. Molecular Cancer 2012, 11:49 Page 8 of 12
http://www.molecular-cancer.com/content/11/1/49
(See figure on previous page.)
Figure 4 MACC1 SNPs rs4721888, rs975263, rs3735615 and colorectal cancer patients’ survival. OS and MFS of 154 colorectal cancer
patients was analyzed with respect to A) SNPs rs4721888, rs975263, rs3735615 vs. no variants, B) variant 31 LL vs. 31 LV, C) 515 SS vs. 515 SL, D)
804 RR vs. 804 RT/TT, E) 804 RR/RT vs. 804 TT. Significant differences of survival times in comparison to MACC1 SNPs were not found. Survival
rates were assessed using the Kaplan-Meier method and differences between groups were assessed using the Log-Rank tests.
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median follow-up time was 5.7 years, for 515 SL 6.4
years and for 804 RT or 804 TT 6.2 years. Overall sur-
vival was calculated from date of histopathological diag-
nosis to the date of death from any cause; patients
known to be alive at last contact were censored.
Metastasis-free survival was determined from the date of
histopathological diagnosis to the time on which the de-
velopment of distant metastasis was observed.Table 2 Characteristics of colorectal cancer patientsMicrodissection and isolation of DNA and RNA
Serial cryosections of each tissue were evaluated by a path-
ologist. The tumor cell populations were microdissected
and the DNA was isolated with the QIAamp Minikit (Qia-
gen) according to the manufacturer’s protocol. Total RNA
was extracted by TRIzol/Chloroform (Invitrogen).Characteristics n (%)
Ethnicity
European 154 (100%)
Gender
Male 79 (51%)
Female 75 (49%)
Age at diagnosis (years)
Median ± SD: 66.32 ±10.44
< 60 40 (26%)
60-70 57 (37%)
> 70 57 (37%)Polymerase chain reaction (PCR) and sequencing
All coding MACC1 exons 4 to 7 and the Met exons 14 to
19 were amplified by PCR. PCR was performed with
proof-reading Pfu DNA polymerase (Fermentas) in a final
volume of 50 μl. Reactions contained 10x Pfu buffer with
2.5 mM MgSO4 (Fermentas), 0.2 mM of each dNTP (Ap-
plied Biosystems), 0.3 μM of each primer, 25 ng DNA and
2.5 u Pfu DNA polymerase. The sequences of primers are
listed in Table 3. Purification and sequencing of PCR pro-
ducts were done by AGOVA GmbH (Berlin).Figure 5 MFS of younger patients with early staged colon
cancer with MACC1 SNP rs975263. 515 SL was associated with
a reduced MFS time of younger colon cancer patients (<60 years,
time at diagnosis) in stage I or II (P = 0.041,
n = 18). P-value was calculated by Log-Rank test.Quantitative reverse transcription–polymerase chain
reaction (qRT-PCR)
QRT-PCR was carried out using the LightCycler480
(Roche) as described previously [4]. QRT-PCR was
performed with the FastStart DNA Master HybProbe
Kit (Roche) according to the manufacturer’s instruc-
tions. The primers and probes are listed in Table 3. In
addition, cDNA quantification of the housekeeping gene
glucose-6-phosphate dehydrogenase (Roche) was per-
formed. For each qRT-PCR reaction a mean of dupli-
cates was calculated and normalized to the respective
mean of the housekeeping gene cDNA.Localisation
Colon 105 (68%)
Rectum 49 (32%)
Metachronous metastasis
With 29 (19%)
Without 125 (81%)
UICC stage
I 26 (17%)
II 74 (48%)
III 54 (35%)
pT status
pT1 + 2 36 (23%)
pT3 + 4 118 (77%)
pN status
Negative 101 (66%)
Positive 53 (34%)
SD indicates the standard deviation. Tumors were classified according to the
guidelines of the nternational Union Against Cancer (UICC) staging system.
International Union Against Cancer (UICC) staging system.
Table 3 Primers and probes used for PCR and qRT-PCR
Gene Primer/Probe Sequence 5’-3’
MACC1, exon 4 Forward primer atctagtcgagtatcctaccag
Reverse primer cagaggtagaccttcaacaattat
MACC1, exon 5.1 Forward primer cttgattgtaactcacagtgcc
Reverse primer gaggttgcctaacatgatttcc
MACC1, exon 5.2 Forward primer gaattccaagaggtgtctctaag
Reverse primer cttcacctgcttccaactgc
MACC1, exon 5.3 Forward primer ggacacaattatatgccaggac
Reverse primer gcagtgtacaagtccaatcttac
MACC1, exon 5.4 Forward primer ggacacaattatatgccaggac
Reverse primer gcagtgtacaagtccaatcttac
MACC1, exon 5.5 Forward primer gcagtgctaagacaaagcaag
Reverse primer catttctcctctcacatggttcag
MACC1, exon 6 Forward primer ctctggcttagttatgtctactg
Reverse primer gtgaatccgtgaatgtggtatg
MACC1, exon 7 Forward primer gtccatgtgtaattggtattccg
Reverse primer tctgagattctttctttcctacac
Met, exon 14 Forward primer gtcgattcttgtgtgctgtctt
Reverse primer cagaggtaaatacttcctttagg
Met, exon 15 Forward primer gctaccactgcttccattcttaaggac
Reverse primer ttgcttccatgcacaagggcaaatcc
Met, exon 16 Forward primer gcttatatccttgggtgaaatgtgttgcatc
Reverse primer atgagggctctgagggatcatttcag
Met, exon 17 Forward primer aaccctcaggacaagatgctaa
Reverse primer ggtgcatttgaatgatgctaacat
Met, exon 18 Forward primer aggcttgagccattaagaccaa
Reverse primer ccagggcttacacatcgattta
Met, exon 19 Forward primer gaggccagatgaaatacttcct
Reverse primer atgaagaaaactggaattggtggt
MACC1, SNP L31V Forward primer gaagctggaaaagtctcaaaaagtt
Reverse primer aactttttgagacttttccagcttc
MACC1, SNP S515L Forward primer taaaaagactcttgaatctgccagg
Reverse primer cctggcagattcaagagtcttttta
MACC1, SNP R804T Forward primer gaaataactacacagatgtgttaca
Reverse primer tgtaacacatctgtgtagttatttc
MACC1, qRT-PCR Forward primer ttcttttgattcctccggtga
Reverse primer actctgatgggcatgtgctg
FITC-probe gcagacttcctcaagaaattctggaagatcta-FITC
LCRed640 LCRed640-agtgtttcagaacttctggacattttagacga
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The MACC1 SNPs L31V, S515L and R804T were intro-
duced into the previously described plasmid pcDNA3.1D/
MACC1-V5-His by site-directed mutagenesis (QuikChange
XL Site-Directed Mutagenesis Kit, Stratagene) [4]. The pri-
mers are summarized in Table 3. The constructs pcDNA3.1/
MACC1/wt, pcDNA3.1/MACC1/L31V, pcDNA3.1/MACC1/
S515L and pcDNA3.1/MACC1/R804T were used for
transfection of colorectal cancer cells.Transfection of SW480, DLD1 and HCT116 cells
Human colorectal cancer cells SW480 were grown in
RPMI-1640 (PAA) containing 10% fetal calf serum (Bio-
chrom), DLD1 and HCT116 cells were grown in DMEM
(PAA) containing 10% fetal calf serum. The cells were
cultured in a humidified 5% CO2 atmosphere. Cells were
analyzed by PCR and found to be free of mycoplasms.
Authentification of SW480, DLD1 and HCT116 cells
was performed by short tandem repeat (STR) genotyping
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genotype was consistent with published genotype. Cells
were transfected with the plasmids pcDNA3.1/MACC1/wt,
pcDNA3.1/MACC1/L31V, pcDNA3.1/MACC1/ S515L,
pcDNA3.1/MACC1/R804T by using Fugene HD (Roche)
according to the manual.
Protein extraction and Western blotting
For protein isolation cells were harvested and incubated
on ice with RIPA buffer (50 mM Tris–HCl pH 7.5, 150
mM NaCl, 1% Nonidet P-40, protease inhibitor tablets;
Roche). Protein concentration was quantified with Coo-
massie Plus (Bradford) Protein Assay (Pierce). Fifty μg of
the lysates were loaded on a NuPAGE Bis-Tris Gel (Invi-
trogen), separated, and transferred onto a nitrocellulose
membrane. Membranes were incubated in blocking solu-
tion and afterwards incubated with rabbit anti-human
MACC1 (1:1.000, Sigma) or mouse anti-human β-
tubulin (1:1.000, BD Pharmingen) antibody, and subse-
quently with HRP-conjugated anti-rabbit IgG (1:10.000,
Promega) or goat anti-mouse IgM (1:10.000, Sigma)
antibody, respectively. At least 3 independent experi-
ments were performed.
Migration, proliferation and wound healing assays
Cell migration assay of the cell lines SW480, DLD1,
HCT116 and their cell clones was performed in transwell
Boyden chambers (Invitrogen). Cells that passed the pores
and migrated through the lower chamber were counted
after 24 h. For the proliferation assays cells were trea-
ted daily with 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2
H-tetrazolium bromide (MTT; Sigma), crystallized
MTT was resolved with dimethylsulfoxid (Applichem),
and the optical density was measured at 560 nm. For the
wound healing assays cells were seeded into wells,
scratched, and the wound healing area was documented
until day 4. Assays were repeated 3 times for each clone,
respectively.
Statistics
Statistical analysis was performed with GraphPad Prism
version 5. The comparison of two groups was done by
two-sided Student’s t-test. Several groups were compared
by one-way analysis of variance (ANOVA) and Bonfer-
roni post hoc multiple comparison. The significance of
clinical parameters was evaluated by Mann–Whitney
tests and Chi-Square-tests with one degree of freedom.
The odds ratio (OR) or hazard ratio (HR) with corre-
sponding 95% confidence intervals (CI) were calculated.
The Kaplan–Meier method was used to estimate cumu-
lative survival rates, and differences in survival rates
were assessed using the Log-Rank test. The OEGE soft-
ware was used for testing the Hardy-Weinberg equilib-
rium (HWE) using the Chi-Square-test with one degreeof freedom [24]. For the determination of the linkage
disequilibrium the correlation coefficient r2 and D’ was
calculated by using OEGE software [25]. Statistical sig-
nificance was considered for P < 0.05.
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Additional file 1: Table S1. Summary of tissues obtained from 154
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